Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of apatinib + capecitabine in platinum-failed recurrent/metastatic nasopharyngeal carcinoma
ChiCTR1800017229Phase 2Completed
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Aug 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib and capecitabine in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Objective tumor remission rate. Started Aug 2018; status: completed.
02
Drugs
Rivoceranibcapecitabine
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR1800017229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800017229.